October 7, 2022
On October 4, Willkie client Stanley Capital Partners announced its acquisition of a majority stake in French pharmaceutical group Laboratoire XO.
The acquisition was financed from a mixture of committed funding facilities and debt funding from Ares Management.
Stanley Capital is expected to work alongside Laboratoire XO’s management team to strengthen and develop the company through add-on acquisitions to help expand the company’s portfolio of essential drugs.
Headquartered in Saint Cloud, France, and founded in 2015, Laboratoire XO specializes in mature market authorizations to sell and market drugs across various therapeutic areas such as pain, central nervous system, cardiology, oral care, and women’s health. Laboratoire XO has a turnover of €60 million, 26 brands, and a distribution network of more than 45 countries.
Founded in 2019, Stanley Capital is a UK-based mid-market private equity firm focused on healthcare, technology and resource efficiency sectors. The completion of this investment brings the firm’s assets under management to $440 million.
Willkie previously represented Stanley Capital in its acquisition of Drug Safety and Pharmacovigilance Services Solutions.
The Willkie team was led by partner Gavin Gordon and included partners Sebastian FitzGerald and Komal Raina, and included associates Amelia Doughty, Autri Saha, Lindsay Murray and Jack Michaels.
